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Covalent  modifications  of  histone  tails  by 
methylation,  acetylation  and  other  changes  play  an 
important  role  in  the  regulation  of  gene  expression, 
notably in the context of developmental decisions and cell 
fate.  Two reports, including one in the December issue of 
Oncotarget, describe the use of whole exome sequencing 
to identify mutations in the histone modifying enzyme 
EZH2 in Weaver syndrome, a rare developmental disorder 
characterised by generalised overgrowth, characteristic 
facial features and intellectual disability [1,2]. The findings 
are remarkable because EZH2 has strong credentials as 
either an oncogene or as a tumour suppressor in a variety 
of malignancies as a consequence of somatically acquired 
mutations.  
EZH2 is the catalytic component of the polycomb 
repressive  complex  2  (PRC2),  which  methylates 
histone H3 lysine 27, resulting in a mark (H3K27me3) 
that  specifies  a  transcriptionally  repressive  chromatin 
environment. PRC2 consists of an additional two core 
components, SUZ12 and EED, which are required for 
complete function and stability of the complex. Elevated 
expression  of  EZH2  has  been  reported  in  a  number 
of  epithelial  and  hematological  malignancies  and  is 
associated  with  an  adverse  prognosis  in  prostate  and 
breast  cancer.  Furthermore,  overexpression  has  been 
causally linked to genomic deletion of microRNA-101 
[3]. Consistent with an oncogenic role, monoallelic gain-
of-function missense mutations at EZH2 tyrosine 641 
have been found in B-cell lymphomas of germinal center 
origin that synergize with wild type EZH2 to result in 
increased levels of H3K27me3 [4]. In contrast, the EZH2 
mutations seen in myeloproliferative neoplasms (MPN) 
and myelodysplastic syndromes (MDS) are inactivating, 
dispersed throughout the gene, may be monoallelic or 
biallelic and are associated with an adverse prognosis [5]. 
The finding of both gain-of function and loss-of-function 
EZH2 mutations is consistent with models suggesting 
that a critical balance of polycomb activity is essential 
for normal stem cell activity, with either loss or gain of 
polycomb function being potentially tumorigenic [6]. 
The mutations seen in Weaver syndrome patients 
are mostly missense substitutions or indels that preserve 
the reading frame, although three cases with truncating 
mutations involving the terminal exon were seen. Although 
not  assessed  functionally,  several  Weaver  syndrome 
mutations are identical to some of the somatic changes 
described in MPN and MDS patients, strongly suggesting 
that they confer a loss-of-function. Despite this, only two 
of  the  19  EZH2-mutated  Weaver  syndrome  identified 
by Tatton-Brown and colleagues developed a malignant 
disorder [1]. Of these, one developed neuroblastoma and 
acute lymphoblastic leukemia at the age of 13 months and 
the second developed lymphoma at 12 years. It should be 
noted however that the eldest case in this series was only 
27 years and that the natural history of Weaver syndrome 
remains under-investigated. It remains to be seen if there is 
a propensity to develop myeloid malignancies later in life. 
Clearly though, inherited EZH2 mutations do not strongly 
predispose to early-onset myeloid malignancies, a fact that 
at first sight is somewhat surprising given the suggestion 
that acquisition of somatic EZH2 mutations is an early 
event in the multistep pathogenesis of these disorders [5]. 
It will be important to determine if the mutations seen in 
Weaver syndrome are perhaps a relatively mild subset of 
mutations seen in MPN and MDS patients. In addition, 
inactivating mutations in SUZ12 and EED are seen in 
hematological  malignancies  [7]  and  these  genes  are 
obvious candidates for EZH2-wild type cases of Weaver 
syndrome or related overgrowth disorders. 
Clinically,  Weaver  syndrome  is  closely  related 
to  Sotos  syndrome,  which  is  frequently  caused  by 
mutations in NSD1. This gene also encodes a histone 
methyltransferase,  in  this  case  with  activity  against 
histone H3 lysine 36. NSD1 is mutated in carcinoma of 
the upper aerodigestive tract (www.sanger.ac.uk/genetics/
CGP/cosmic/)  and also fuses to NUP98 in acute myeloid 
leukemia. Looking more widely, whole exome screens 
in lymphoma, multiple myeloma, renal carcinoma and 
other  malignancies  have  identified  genes  encoding 
diverse histone modifiers as targets of somatic mutation. 
Strikingly, several of these (e.g. MLL2, EP300, CREBBP, 
ASXL1)  are  also  mutated  in  human  developmental 
disorders  thus  pointing  towards  a  remarkable  and 
unexpected convergence between somatic and germline 
genetics. 
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